-
Breakthrough Results: Encaleret Shows Promise for Autosomal Dominant Hypocalcemia Type 1
NASDAQ: $BBIO A New Frontier in Treating ADH1 Recent results from the Phase 3 CALIBRATE trial have brought a wave of optimism for patients living with Autosomal Dominant Hypocalcemia Type 1 (ADH1). The trial evaluated the efficacy and safety of encaleret, an investigational therapy designed to address the underlying physiological challenges of this rare genetic…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 03-01-2026 TO 03-07-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-22-2026 TO 02-28-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$ALDX, $ALXO, $BBIO, $CGEN, $FULC, $GANX, $IMRX, $TARA, $XNCR, ASCO Genitourinary Cancers Symposium, biopharmaceutical, clinical-research, fda, new drug application, Oppenheimer 36th Annual Healthcare Life Sciences Conference, pr-newswire, press-releases, Wells Fargo Executive Biotech Summit, World ADC London 2026